March 2, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares over potential securities laws violations by Momenta Pharmaceuticals, Inc. (and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning whether a series of statements by Momenta Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Momenta Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $52.25 million in 2014 to $109.62 million in 2016 and that its Net Loss declined from $98.60 million in 2014 to $21.00 million in 2016.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) grew from $8.46 per share in March 2016 to as high as $19.35 per share on February 1, 2017.

On February 17, 2017, Momenta Pharmaceuticals, Inc. disclosed that a contracted Pfizer facility used to manufacture the Company's Glatopa product had received a warning letter from the U.S. Food and Drug Administration ('FDA'). Momenta Pharmaceuticals, Inc's Abbreviated New Drug Application for its Glatopa 40 mg product candidate remains under regulatory review, and under FDA policy, final approval is dependent on the satisfactory resolution of the compliance observations at the Pfizer manufacturing facility.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) declined on February 21 2017 to as low as $14.42 per share.

On March 2, 2017, NASDAQ:MNTA shares closed at $14.80 per share.